Clinical trial
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With…
NCT00487708 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00487708 |
|---|---|
| Title | Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms |
| Official title | An Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | NALP3 Mutation |
| Intervention type | Drug |
| Interventions | canakinumab |
| Enrollment | 34 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 19, 2007 |
| Last update posted | Feb 17, 2009 |
| Countries | France, Germany, India, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: